Interference with vancomycin fluorescence polarisation immunoassay in a nonuraemic patient.
Commercially available immunoassays for vancomycin have been reported to overestimate serum vancomycin concentrations by varying degrees in patients with renal impairment, particularly those on peritoneal dialysis, by interference with crystalline degradation product-1 (CDP-1). To date this interference has not been reported in any other patient population. This report describes vancomycin fluorescence polarisation immunoassay (FPIA) interference in a patient with only mildly impaired renal function. At this time it is not possible to confirm that the interference was caused by CDP-1.
Bowhay
S
S
Clinical Pharmacokinetics Laboratory, Stobhill N.H.S. Trust, Glasgow, Scotland.
Timms
P
P
D000900:Anti-Bacterial Agents / Q000097:blood* / Q000627:therapeutic use; D003429:Cross Reactions; D017248:Enzyme Multiplied Immunoassay Technique; D016231:Fluorescence Polarization Immunoassay; D006801:Humans; D007674:Kidney Diseases / Q000097:blood / Q000150:complications; D008297:Male; D008875:Middle Aged; D013203:Staphylococcal Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy; D013212:Staphylococcus epidermidis; D014640:Vancomycin / Q000097:blood* / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D014640:Vancomycin